Use of rasagilline for the treatment of restless legs syndrome
AssigneeTeva Pharmaceutical Industries Ltd.
InventorsEran Blaugrund, Ruth Levy
Life of this patent
Estimating the term…
Abstract
Methods for the treatment of Restless Legs Syndrome using R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof.
Claims29
A method of treating a subject suffering from Restless Legs Syndrome which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptably salt thereof effective to treat the subject, wherein the efficacy of treatment is measurable by change of the International Restless Legs Scale (IRLS) score and the IRLS score of the subject decreases by at least 50% compared to baseline.
A method of alleviating a symptom of Restless Legs Syndrome in a subject afflicted with Restless Legs Syndrome comprising administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof effective to alleviate the symptom of Restless Legs Syndrome in the subject, wherein the efficacy of treatment is measurable by change of the International Restless Legs Scale (IRLS) score and the IRLS score of the subject decreases by at least 50% compared to baseline.
A method of treating a male subject suffering from Restless Legs Syndrome which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptably salt thereof effective to treat the subject.
A method of alleviating a symptom of Restless Legs Syndrome in a male subject afflicted with Restless Legs Syndrome comprising administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof effective to alleviate the symptom of Restless Legs Syndrome in the subject.
Dependencies are inferred from the claim text.